Suchergebnisse - "YO603Y8113"

PubPharm (1.117)

31

HIV-1 protease inhibitors with a P1 phosphonate modification maintain potency against drug-resistant variants by increased interactions with flap residues

enthalten in: European journal of medicinal chemistry | 2023

von Lockbaum, G. | Rusere, L. | Henes, M. | +9

32

Maintenance darunavir/ritonavir monotherapy to prevent perinatal HIV transmission, ANRS-MIE 168 MONOGEST study

enthalten in: The Journal of antimicrobial chemotherapy | 2023

von Mandelbrot, L. | Tubiana, R. | Frange, P. | +114

33

A four-drug combination oral tablet of darunavir, cobicistat, emtricitabine, and tenofovir alafenamide for the treatment of HIV-1 infection in adults

enthalten in: Expert review of anti-infective therapy | 2023

von Muccini, C. | Castagna, A.

34

Immune response to ART initiation in advanced HIV infection

enthalten in: HIV medicine | 2023

von Mounzer, K. | Brunet, L. | Fusco, J. | +5

35

HIV-1 genotypic profiling ensures effective response to third-line antiretroviral therapy in Cameroon

enthalten in: Medicine | 2023

von Mbouyap, P. | Fokam, J. | Ngoufack Jagni Semengue, E. | +12

36

Effect of doravirine on dolutegravir trough concentrations in people with HIV switched from darunavir/cobicistat

enthalten in: The Journal of antimicrobial chemotherapy | 2023

von Cattaneo, D. | Pagano, S. | Antinori, S. | +3

37

Efficacy and Durability of Dolutegravir- or Darunavir-Based Regimens in ART-Naïve AIDS- or Late-Presenting HIV-Infected Patients

enthalten in: Viruses | 2023

von Fabbiani, M. | Masini, M. | Rossetti, B. | +13

38

Immune recovery among Romanian HIV/AIDS patients receiving darunavir/ritonavir or darunavir/cobicistat regimens in cART management : A three-year study

enthalten in: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie | 2023

von Marin, R. | Bungau, S. | Tit, D. | +3

39

PRESTIGIO RING : "A 59-year-old HIV-1 positive, highly treatment-experienced woman failing darunavir/ ritonavir plus raltegravir"

enthalten in: The new microbiologica | 2023

von Labate, L. | Bruzzone, B. | Spagnuolo, V. | +4

40

Mechanistic in vitro studies indicate that the clinical drug-drug interactions between protease inhibitors and rosuvastatin are driven by inhibition of intestinal BCRP and hepatic OATP1B1 with minimal contribution from OATP1B3, NTCP and OAT3

enthalten in: Pharmacology research & perspectives | 2023

von Elsby, R. | Coghlan, H. | Edgerton, J. | +3